DEXMEDETOMIDINE HYDROCHLORIDE (dexmedetomidine) by Viatris (2) is 2 -adrenergic agonist with sedative properties. First approved in 2014.
Drug data last refreshed 19h ago
2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10-300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥ 1,000 mcg/kg) or with rapid…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Effect of Perioperative Dexmedetomidine on Chronic Post-Surgical Pain
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
Postoperative Dexmedetomidine in Prevention of Postoperative Delirium
Different Administration Routes of Dexmedetomidine on Postoperative Delirium
Worked on DEXMEDETOMIDINE HYDROCHLORIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.